Selecting Therapy for Advanced NSCLC Based on PDL1 and NGS Testing

Shared insight on the value that molecular testing and PDL1 testing, respectively, have on determining optimal therapy for patients with advanced non–small cell lung cancer.

Related Keywords

,Recent Updates ,Translating Evidence ,Clinical Practice ,Lung Cancer ,Non Small Cell Lung Cancer ,Nsclc ,Trio Therapy ,Immunotherapy ,Immune Checkpoint Inhibitors ,Metastatic Nsclc ,Metastatic Lung Cancer ,Rings ,Next Generation Sequencing ,Ktmb ,Tumor Mutational Burden ,Molecular Testing ,Genetic Testing ,Ipi Nivo ,Nivo Ipi ,Ipilimumab ,Nivolumab ,Pdl1 Levels ,Pdl1 Expression ,